Elicio Therapeutics, Inc. SEC filings ELTX
Elicio Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Mar 4, 2014. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 16, 2026 | — |
| CORRESP | Letter to the SEC | Mar 12, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2026 | — |
| EFFECT | Filing | Dec 3, 2025 | — |
| CORRESP | Letter to the SEC | Dec 1, 2025 | — |
| EFFECT | Filing | Nov 20, 2024 | — |
| CORRESP | Letter to the SEC | Nov 18, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2024 | — |
| EFFECT | Filing | Jun 11, 2024 | — |
| EFFECT | Filing | Jun 11, 2024 | — |
| CORRESP | Letter to the SEC | Jun 10, 2024 | — |
| CORRESP | Letter to the SEC | Jun 7, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2024 | — |
| CORRESP | Letter to the SEC | Jun 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2024 | — |
| D | Filing | Mar 29, 2024 | — |
| D | Filing | Jan 5, 2024 | — |
| 425 | Filing | May 30, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| SEC STAFF LETTER | Filing | Apr 28, 2023 | — |
| EFFECT | Filing | Apr 28, 2023 | — |
| CORRESP | Letter to the SEC | Apr 26, 2023 | — |
| CORRESP | Letter to the SEC | Apr 21, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2023 | — |
| CORRESP | Letter to the SEC | Apr 13, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2023 | — |
| SEC STAFF LETTER | Filing | Apr 6, 2023 | — |
| CORRESP | Letter to the SEC | Mar 29, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2023 | — |
| 425 | Filing | Jan 18, 2023 | — |
| 425 | Filing | Jan 18, 2023 | — |
| 425 | Filing | Jan 18, 2023 | — |
| 425 | Filing | Jan 17, 2023 | — |
| 425 | Filing | Jan 17, 2023 | — |
| EFFECT | Filing | May 23, 2022 | — |
| UPLOAD | Letter from the SEC | May 19, 2022 | — |
| CORRESP | Letter to the SEC | May 19, 2022 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| CERT | Filing | Feb 4, 2021 | — |
| 8-A12B/A | Filing | Feb 4, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| 8-A12B | Filing | Feb 2, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 26, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2020 | — |
| DRSLTR | Filing | Dec 15, 2020 | — |
| DRS/A | Filing | Dec 15, 2020 | — |
| D | Filing | Jun 23, 2020 | — |
| UPLOAD | Letter from the SEC | May 27, 2020 | — |
| DRSLTR | Filing | May 13, 2020 | — |
| DRS/A | Filing | May 13, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2020 | — |
| SEC STAFF LETTER | Filing | Mar 10, 2020 | — |
| DRS | Filing | Feb 14, 2020 | — |
| D | Filing | Jan 27, 2020 | — |
| D | Filing | Jan 13, 2020 | — |
| D | Filing | Jul 17, 2018 | — |
| D | Filing | Jul 17, 2018 | — |
| D | Filing | Feb 20, 2015 | — |
| RW | Filing | Oct 24, 2014 | — |
| DRS | Filing | Mar 4, 2014 | — |
Showing 63 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1601485
- Former names
- Angion Biomedica Corp. (until May 30, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.